Abstract
In ageing, the accumulation of damaged molecules provoked by oxidative stress and inflammation contributes to altered gene expressions and cellular dysfunction. The antioxidant system is crucial in order to prevent damage to intracellular molecules including DNA and, consequently, to avoid cellular dysfunction or neoplastic transformation. However, during serious DNA damage, the cells can activate a response characterized by cell cycle arrest and production of factors (mainly chemokines and cytokines) named “senescent associated secretory phenotype” (SASP) with the putative function to attract immune cells involved in the clearance of the senescent cells. This phenomenon named “cellular senescence” is, by one side, an important tumor suppressive mechanism but, on the other side, it contributes to impair tissue regenerative capacity and to possible transformation of neighbouring cells to cancer cells if a rapid clearance of the senescent cell doesn’t occur. Therefore, preventing DNA damage via an optimal intracellular antioxidant defence is the key to reduce risk of cancer while keeping senescent changes at minimum. Zinc-bound Metallothioneins (MT), could play a key role in this prevention because they are antioxidant proteins and release zinc ions for several proteins and enzymes involved in antioxidant and DNA-repair responses. Reduced MT expression and intracellular zinc occur in some models of senescent cells. This process is of relevance since zinc ions released from MT could be implicated in the modulation of SASP. In chronic inflammation, such as in ageing, the dysfunction in zinc release from MT occurs, suggesting a potential contribution to the onset of senescent cells. Hence, MT could be directly or indirectly involved in the modulation of cellular senescent state and might represent a possible therapeutic target against the accumulation of dysfunctional senescent cells.
Keywords: Metallothioneins, ageing, cellular senescence, inflammation, MT-target therapeutic approach, cellular dysfunction, antioxidant system, cancer, chemokines, cytokines
Current Pharmaceutical Design
Title:Metallothioneins, Ageing and Cellular Senescence: A Future Therapeutic Target
Volume: 19 Issue: 9
Author(s): Eugenio Mocchegiani, Laura Costarelli, Andrea Basso, Robertina Giacconi, Francesco Piacenza and Marco Malavolta
Affiliation:
Keywords: Metallothioneins, ageing, cellular senescence, inflammation, MT-target therapeutic approach, cellular dysfunction, antioxidant system, cancer, chemokines, cytokines
Abstract: In ageing, the accumulation of damaged molecules provoked by oxidative stress and inflammation contributes to altered gene expressions and cellular dysfunction. The antioxidant system is crucial in order to prevent damage to intracellular molecules including DNA and, consequently, to avoid cellular dysfunction or neoplastic transformation. However, during serious DNA damage, the cells can activate a response characterized by cell cycle arrest and production of factors (mainly chemokines and cytokines) named “senescent associated secretory phenotype” (SASP) with the putative function to attract immune cells involved in the clearance of the senescent cells. This phenomenon named “cellular senescence” is, by one side, an important tumor suppressive mechanism but, on the other side, it contributes to impair tissue regenerative capacity and to possible transformation of neighbouring cells to cancer cells if a rapid clearance of the senescent cell doesn’t occur. Therefore, preventing DNA damage via an optimal intracellular antioxidant defence is the key to reduce risk of cancer while keeping senescent changes at minimum. Zinc-bound Metallothioneins (MT), could play a key role in this prevention because they are antioxidant proteins and release zinc ions for several proteins and enzymes involved in antioxidant and DNA-repair responses. Reduced MT expression and intracellular zinc occur in some models of senescent cells. This process is of relevance since zinc ions released from MT could be implicated in the modulation of SASP. In chronic inflammation, such as in ageing, the dysfunction in zinc release from MT occurs, suggesting a potential contribution to the onset of senescent cells. Hence, MT could be directly or indirectly involved in the modulation of cellular senescent state and might represent a possible therapeutic target against the accumulation of dysfunctional senescent cells.
Export Options
About this article
Cite this article as:
Mocchegiani Eugenio, Costarelli Laura, Basso Andrea, Giacconi Robertina, Piacenza Francesco and Malavolta Marco, Metallothioneins, Ageing and Cellular Senescence: A Future Therapeutic Target, Current Pharmaceutical Design 2013; 19 (9) . https://dx.doi.org/10.2174/1381612811319090022
DOI https://dx.doi.org/10.2174/1381612811319090022 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Is the Expression of Deoxynucleoside Kinases and 5'-nucleotidases in Animal Tissues Related to the Biological Effects of Nucleoside Analogs?
Current Medicinal Chemistry NK Cell, Monocyte and Non T Cell Biomarkers as Prognostic Indicators in Cancer Immunotherapy
Current Cancer Therapy Reviews Peptide Vaccines for Cancer Therapy
Recent Patents on Inflammation & Allergy Drug Discovery Anti-Carcinogenic Effects of Carnosol-An Updated Review
Current Drug Discovery Technologies Metastatic Cancer Stem Cells: New Molecular Targets for Cancer Therapy
Current Pharmaceutical Biotechnology GPER and ER: Estrogen Receptors with Distinct Biological Roles in Breast Cancer
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Tangy Scent in Toona sinensis (Meliaceae) Leaflets: Isolation, Functional Characterization, and Regulation of TsTPS1 and TsTPS2, Two Key Terpene Synthase Genes in the Biosynthesis of the Scent Compound
Current Pharmaceutical Biotechnology SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target
Current Pharmaceutical Design Integrins: Regulators of Tissue Function and Cancer Progression
Current Pharmaceutical Design Histone Modifier Differentially Regulates Gene Expression and Unravels Survival Role of MicroRNA-494 in Jurkat Leukemia
MicroRNA Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT
Current Pharmaceutical Design Plant Coumestans: Recent Advances and Future Perspectives in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry A Descriptive Analysis of Post-Chemotherapy Development of Interstitial Lung Disease Using Spontaneous Reporting Data in Japan
Current Drug Safety Synthesis, Radiosynthesis and Metabolism of 131I-Y-c(CGRRAGGSC)
Anti-Cancer Agents in Medicinal Chemistry Disulfiram's Anticancer Activity: Evidence and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway
Anti-Cancer Agents in Medicinal Chemistry Anti-angiogenic Therapy and Induction of Blood Vessel Normalization in the Treatment of Ovarian Cancer
Current Angiogenesis (Discontinued) Recent Advances in the Development of Selective Small Molecule Inhibitors for Cyclin-Dependent Kinases
Current Topics in Medicinal Chemistry MicroRNAs and Cancer; an Overview
Current Pharmaceutical Biotechnology